FOLH1 and prostate carcinoma: Later, in 2020, the first prostate-specific membrane antigen (PSMA) targeted radiotracer [68Ga]Ga-PSMA-11 was approved for PET imaging in prostate cancer (PCa) patients, followed by the approval of the first PSMA-targeted therapeutic radiotracer [177Lu]Lu-PSMA-617 (Pluctivo®) in 2022 for the treatment of positive metastatic castration-resistant PCa patients [12, 13].